Drug-Induced Psychosis After Long-Term Treatment With Levetiracetam
Dear Editor: Psychiatric adverse effects are an often-seen feature of treatment with newer antiepileptic drugs. Levetiracetam is a new anticonvulsant with an unknown mechanism of action. There have been some reports about levetiracetam-induced psychosis, mainly in children (1, 2) . To our knowledge, all cases occurred at the onset of levetiracetam intake. We report on the case of a woman, aged 30 years, who developed psychotic syndromes after an increase in levetiracetam dosage.
Case Report
Mrs H had an 11-year history of myoclonal epilepsia of unknown etiology. The patient was admitted to our department owing to levetiracetam-induced psychosis by the neurological department, where she had been treated for 11 days prior. On admission to the neurological department, Mrs H had been treated with levetiracetam 1750 mg and lamotrigine 275 mg. After 3 days, primidone 250 mg was added to therapy, and on the following day, the levetiracetam dosage was increased to 2250 mg. Since admission, she had been seizure free. During the evening of the ninth and the following day after admission, she was agitated and nervous. The following day she was afraid of suffering new seizures, was distrustful, and refused to take further medication. There was some evidence of acoustic hallucinations also, but the patient denied these. The next day she showed aggressive tendencies toward the nurses and tried to leave the hospital. She was admitted to our acute psychiatric ward, where restraint was necessary. On admission she screamed, talked to imaginary persons, was agitated, and showed aggressive behaviour. We started medication with lorazepam 2 mg, zuclopenthixol 25 mg, and diazepam 10 mg. The levetiracetam dosage was reduced to 1500 mg, and lamotrigine and primidone were continued unchanged. The following day intake of olanzapine 10 mg was started. Restraint was necessary for the first 2 days. On the evening of the second day, she calmed down and regained orientation and insight into her illness. On the third day, she reported acoustic hallucinations again: a female voice told her she had been given the wrong medicine. On the fourth day, her overall behaviour returned to normal, and she was readmitted to the neurological department.
In the literature, prevalence rates of levetiracetam-induced psychosis range from less than 1% to 1.4% (3) (4) (5) . Mula and others report certain risk factors, including a history of febrile convulsions, status epilepticus or previous psychiatric history, or lamotrigine cotherapy (5) . Only lamotrigine cotherapy was given in our patient. Levetiracetaminduced psychosis normally occurs about 1 week after the start of treatment. In our case, the patient received a stable dosage of levetiracetam for about 1 year, with psychosis occurring 1 week after the dosage was increased. However, psychosis is a side effect of levetiracetam therapy that can also occur after long-term treatment. In certain patients, risk-factors should be clinically monitored, specifically when the dosage is changed.
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Priapism
Dear Editor: Priapism is a rare but serious side effect of antipsychotic medication. Cases of ischemic priapism have been reported with most atypical antipsychotics (ATPs) (1) . Priapism, which has both ischemic and high-flow subtypes, can also be associated with hematologic and vascular abnormalities, as well as spinal cord injury, neoplasms, and prostatitis. We present the case of a man who developed ischemic priapism on 3 occasions, while on 3 different ATPs.
Mr A is aged 44 years with a 23-year history of schizophrenia. He was taking risperidone 4 mg orally twice daily and trazodone 150 mg orally at bedtime when he first developed priapism. He received saline and phenylephrine cavernosal irrigation in emergency after having the priapism for 7 hours. We changed his treatment to quetiapine up to 600 mg daily. He developed ischemic priapism 24 days after starting quetiapine. Again, he required cavernosal irrigation to resolve a 10-hour period of priapism. We then treated him with olanzapine up to 20 mg daily. He developed ischemic priapism 53 days after starting olanzapine. This episode responded to phenylephrine 60 mg orally. Following this episode, we discovered that his fasting blood sugars were consistently greater than 15 mmol/L. His hemoglobin was 120 g/L. During the previous 2 years, his fasting blood sugars had ranged from 4.6 to 8.5 mmol/L. Further workup, including a CT scan of his pelvis, was negative. He was started on insulin and loxapine, and his fasting blood sugars normalized. We chose loxapine because it has minimal alpha 1 adrenoceptor blockade (2) . He had no further episodes of priapism.
The patient had previously been on risperidone up to 8 mg daily with trazodone 50 to 100 mg daily for 2 years. He then had a 4-month trial of quetiapine up to 700 mg daily with trazodone 50 to 100 mg daily. He had no documented episodes of priapism during this period. His blood sugars were normal at that time. This case illustrates the potential risk of ischemic priapism from a range of ATPs aggravated by diabetes. The capacity for each of the pharmacologic agents to induce alpha 1 adrenoceptor blockade is likely the common denominator for the drug-induced priapism. All ATPs block alpha 1 adrenoceptors (3). Olanzapine has little action on alpha 2 adrenoceptors (3). Blockade of the sympathetic nervous system prevents its normal inhibitory influence on corpus cavernosal smooth muscle and on penile vascular inflow resistance. Both are required in mediating detumescence or maintaining a flaccid state. The high blood sugars likely facilitated the development of priapism by altering the normal status of the sympathetic nervous system systemically.
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